相关实验视频

Updated: Jun 5, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

激素受体阳性和HER2-阴性转移性乳腺癌的替代Palbociclib剂量表

Makiko Go¹, Michio Kimura², Shiori Yamada²

¹Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan, m_go5252@yahoo.co.jp.

|December 11, 2024

概括

替代的帕尔博西克利布剂量计划,如3/2和2/2,可以有效地管理转移性乳腺癌患者的中性质衰竭,保持治疗疗效和改善与标准3/1计划相比的结果.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

作为CDK4/6抑制剂的Palbociclib经常与中性质减退有关,使治疗的延续复杂化.
由于不良事件,通常很难维持标准的3/1剂量计划 (3周,1周休息).
已经探索了替代的palbociclib剂量计划,以提高治疗耐受性和持续性.

研究的目的:

在HR+/HER2-转移性乳腺癌患者中研究替代palbociclib剂量表的有效性和可行性.
在不同方案中比较治疗持续时间,相对剂量强度 (RDI),整体反应率 (ORR) 和临床益处率 (CBR).

主要方法:

在2018年1月至2023年11月期间接受Palbociclib治疗的HR+/HER2-MBC患者的回顾性分析.
患者被分为标准的3/1,3/2或2/2剂量计划组.
收集的数据包括治疗持续时间,RDI,ORR,CBR以及电子医疗记录中的不良事件.

主要成果:

与3/1方案 (255.5天) 相比,替代的3/2和2/2方案的平均治疗持续时间 (分别为1,253.0天和923.0天) 显著更长.
3/2计划 (69.2%) 和3/1计划 (71.0%) 保持了高于2/2计划 (40.8%) 的中位数RDI.
3/2计划实现了100%的CBR和80.0%的ORR,明显超过了3/1计划 (55.0%的CBR,15.0%的ORR).

结论:

替代的Palbociclib剂量表 (3/2和2/2) 可以有效地用于继续治疗HR+/HER2-MBC患者.
这些替代方案显示出有前途的治疗效果,3/2方案显示出优异的结果.
需要进一步的前性研究与更大的队列来验证这些发现,并优化palbociclib治疗策略.

关键词:

替代剂量计划替代剂量计划这是一种CDK4/6抑制剂.它是HER2阴性的.具有激素受体阳性的人.转移性乳腺癌是发生转移的

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Dosage Regimen: Fixed Dose

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...